Search results
Results from the WOW.Com Content Network
The most frequent side effects include headache, insomnia, sleepiness, parkinsonism (effects similar to Parkinson's disease such as shaking, muscle stiffness and slow movement), dystonia (involuntary muscle contractions), tremor (shaking), dizziness, akathisia (restlessness), agitation, anxiety, depression, increased weight, nausea, vomiting, constipation, dyspepsia (heartburn), diarrhea, dry ...
Ephenidine (also known as NEDPA and EPE) is a dissociative anesthetic that has been sold online as a designer drug. [1] [2] It is illegal in some countries as a structural isomer of the banned opioid drug lefetamine, but has been sold in countries where it is not yet banned. [3] [4]
Biperiden, sold under the brand name Akineton among others, is a medication used to treat Parkinson disease, certain drug-induced movement disorders [2] and Tourette Syndrome [citation needed]. It is not recommended for tardive dyskinesias. [3] It is taken by mouth, injection into a vein, or muscle. [2] [3]
Epinephrine, also known as adrenaline, is a medication and hormone. [10] [11] As a medication, it is used to treat several conditions, including anaphylaxis, cardiac arrest, asthma, and superficial bleeding. [8] Inhaled epinephrine may be used to improve the symptoms of croup. [12] It may also be used for asthma when other treatments are not ...
Pethidine is the preferred drug for the management of shivering during therapeutic hypothermia, as it provides the greatest reduction in the shivering threshold. [ 20 ] Before 2003, it was on the World Health Organization's List of Essential Medicines , the most effective and safe medicines needed in a health system.
Indapamide is a thiazide-like diuretic [4] drug used in the treatment of hypertension, as well as decompensated heart failure.Combination preparations with perindopril (an ACE inhibitor antihypertensive) are available.
Daridorexant is indicated for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. [1] The medication has been found to significantly improve latency to persistent sleep (LPS), wake after sleep onset (WASO), and subjective total sleep time (TST) in regulatory clinical trials. [1]
New Drug Applications (NDA) for eteplirsen and a similar drug drisapersen were filed with the US Food and Drug Administration (FDA) in August 2015. [13] The Prescription Drug User Fee Act (PDUFA) goal dates for these were December 27, 2015 for drisapersen and February 26, 2016, for eteplirsen. Following FDA rejection of drisapersen, the agency ...